DOI : 10.1055/s-00000054

Pharmacopsychiatry

Ausgabe 05 · Volume 40 · September 2007 DOI: 10.1055/s-002-7034


25th Symposium of the AGNP
Munich, 3rd–6th October 2007

Chairs: Prof. Dr. W. Wolfgang Fleischhacker, Innsbruck, Dr. Werner Kadus, Karlsruhe
Abstracts (HTML) Autorenliste
A066
Baier, P. C.; Koch, J. M.; Seeck-Hirschner, M.; Wilms, S.; Hinze-Selch, D.; Aldenhoff, J. B.: NMDA-hyposensitivity in whole blood platelets of amisulpride-treated schizophrenics
A067
Benninghoff, J.; Grunze, H.; Genius, J.; Möller, H. J.; Dehning, S.; Schindler, C.; Rujescu, D.: Enhanced cognition in schizophrenics treated with ziprasidone might rely on migration of adult neural stem cells
A068
Boxleitner, M.; Giegling, I.; Hartmann, A. M.; Muglia, P.; Ruppert, A.; Möller, H. J.; Rujescu, D.: Genetic association study in schizophrenia and intermediate phenotypes
A069
Widschwendter, C. G.; Hofer, A.; Rettenbacher, M. A.; Edlinger, M.; Kemmler, G.; Fleischhacker, W. W.: Drug attitude during the initial treatment period: A prospective follow-up study in patients with schizophrenia
A070
Czekalla, J.; Ibach, B.; Gerwe, M.; Klose, N.; Hargarter, L.; Schreiner, A.: Interim analysis of 2-years non-interventional trial (LARA) shows tendency towards higher treatment adherence with less compliant schizophrenia patients under long-acting injectable risperidone (LAIR) compared to an oral atypicals (OA) treatment cohort
A071
Eichhammer, P.; Landgrebe, M.; Langguth, B.; Sand, P.; Hajak, G.: Neurophysiological aspects of typical and atypical neuroleptic agents
A072
Göder, R.; Fritzer, G.; Gottwald, B.; Lippmann, B.; Seeck-Hirschner, M.; Serafin, I.; Aldenhoff, J. B.: Sleep-related memory consolidation and the effects of olanzapine in patients with schizophrenia
A073
Giegling, I.; Hartmann, A. M.; Genius, J.; Konnerth, H.; Muglia, P.; Ruppert, A.; Möller, H. J.; Rujescu, D.: Members of the forkhead family of transcription factors might be involved in the pathogenesis of schizophrenia
A074
Giegling, I.; Hartmann, A. M.; Genius, J.; Konnerth, H.; Muglia, P.; Ruppert, A.; Möller, H. J.; Rujescu, D.: Differentially expressed genes in an animal model of psychosis associated to schizophrenia within a large case-control study
A075
Gross, S.; Koethe, D.; Hellmich, M.; Kranaster, L.; Hoyer, C.; Schultze-Lutter, F.; Klosterkötter, J.; Leweke, F. M.: Binocular depth inversion illusion for early assessment of altered visual information processing in the course of schizophrenia
A076
Gruber, O.; Meyer, J.; Zilles, D.; Gruber, E.; Falkai, P.: Genetic polymorphisms of serotonergic and dopaminergic neurotransmission differentially affect neurofunctional subsystems of working memory
A077
Hajak, G.; Langguth, B.; Landgrebe, M.; Sand, P.; Eichhammer, P.: Thalamic gating, schizophrenia and antipsychotic treatment – an investigation with TMS
A078
Hartmann, A. M.; Giegling, I.; Genius, J.; Schäfer, M.; Bondy, B.; Möller, H. J.; Rujescu, D.: A study on pharmacogenetics of haloperidol treatment
A079
Hennings, J. M. H.; Krause, E.; Bötzel, K.; Wetter, T. C.: Successful treatment of tardive dyskinesia with botulinum toxin
A080
Henseler, I.; Gruber, O.; Krick, C.; Reith, W.; Falkai, P.: Schizophrenia patients present aberrant brain activation patterns during verbal and spatial working memory tasks: an fMRI study
A081
Hinze-Selch, D.; Däubener, W.; Eggert, L.; Erdag, S.; Stoltenberg, R.; Wilms, S.: A controlled prospective study of Toxoplasma gondii infection in individuals with schizophrenia: Beyond seroprevalence
A082
Meltzer, H.; Hargarter, L.; Kramer, M.; Sherr, J.; Gassmann-Mayer, C.; Lim, P.; Bobo, W.; Eerdekens, M.: Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week placebo-controlled studies (PAL-SCH-303/304/305)
A083
Kleinlogel, H.; Strik, W.; Begré, S.: Increase of P300-NoGo-anteriorisation in first-episode schizophrenia patients during Continuous Performance Test
A084
Ibach, B.; Gerwe, M.; Hargarter, L.; Czekalla, J.: Evaluating decision criteria for the choice of pharmacological long-term therapy in risperidone treated patients with schizophrenia
A085
Ibach, B.; Hargarter, L.; Gerwe, M.; Czekalla, J.: Time to clincal stabilization of in-patients with schizophrenia after conversion to long-acting risperidone
A086
Ihrenberger, C.; Hofer, A.; Benecke, C.; Edlinger, M.; Huber, R.; Kemmler, G.; Rettenbacher, M. A.; Schleich, G.; Fleischhacker, W. W.: Facial emotion recognition and its relationship to symptomatic, subjective, and functional outcomes in outpatients with chronic schizophrenia
A087
Genius, J.; Hartmann, A.; Möller, H. J.; Rujescu, D.: Forkhead box P (foxP) mRNA expression in the rat hippocampus negatively correlates with performance in a spatial memory paradigm
A088
Genius, J.; Braun, I.; Grunze, H.; Benninghoff, J.; Möller, H. J.; Rujescu, D.: Regionally different responses of GABAergic interneuron populations to a NMDA receptor antagonist challenge with MK-801 and an antipsychotic “rescue therapy“ in an animal model of psychosis
A089
Genius, J.; Geiger, J.; Bender, A.; Benninghoff, J.; Möller, H. J.; Rujescu, D.: Creatine mediates neuroprotection towards excitoxicity in an in vitro model of neurodegeneration
A090
Kirschbaum, K. M.; Henken, S.; Hiemke, C.; Schmitt, U.: Pharmacodynamics and pharmacokinetics of risperidone and paliperidone with respect to P-glycoprotein expression
A091
Kirschbaum, K. M.; Uhr, M.; Hiemke, C.; Schmitt, U.: Multi-Drug-Resistance proteins affect antipsychotic treatment: in vivo effects of aripiprazole
A092
Knolle-Veentjer, S.; Huth, V.; Ferstl, R.; Aldenhoff, J.; Hinze-Selch, D.: Delay of gratification and executive performance in individuals with schizophrenia: putative role for eating behavior and body weight regulation
A093
Knolle-Veentjer, S.; Huth, V.; Ferstl, R.; Aldenhoff, J.; Hinze-Selch, D.: Delay of gratification and executive performance in individuals with schizophrenia: putative role for eating behavior and body weight regulation
A094
Kollmar, C. I.; Verner, L.; Dietrich, D.; Lampen-Imkamp, S.: Das maligne neuroleptische Syndrom; Differentialdiagnosen und Therapieoptionen anhand einer Falldarstellung
A095
Konnerth, H.; Giegling, I.; Hartmann, A. M.; Muglia, P.; Möller, H. J.; Rujescu, D.: Neuropsychological endophenotypes as tools for genetic studies in schizophrenia
A096
Kryshanovskaya, L.; Schulz, C.; McDougle, C. J.; Frazier, J. A.; Dittmann, R. W.; Robertson-Plouch, C.; Bauer, T.; Xu, W.; Wang, W. V.; Carlson, J.; Tohen, M.: Olanzapine versus placebo in adolescents with schizophrenia
A097
Kungel, M.; Czaniera, R.; Ebrecht, M.; Werner, C.; Oren, D.; McQuade, R.; Modell, S.: Intramuscular Aripiprazole for the Treatment of Acute Agitation Associated with Schizophrenia: Sub-analysis of a Double-blind, Controlled, Dose-ranging Study
A098
Kungel, M.; Engelhardt, A.; Spevakné-Göröcs, T.; Ebrecht, M.; Werner, C.; Modell, S.: Office-based post-marketing surveillance study on the influence of long term therapy with aripiprazole in patients with schizophrenia
A099
Kungel, M.; Wiesch, A.; Spevakné-Göröcs, T.; Ebrecht, M.; Werner, C.; Modell, S.: Postmarketing surveillance of aripiprazole in a hospital-based setting
A100
Leucht, S.; Kissling, W.; Busch, R.: Early prediction of non-response – when should antipsychotic drugs be switched?
A101
Kramer, M.; Hargarter, L.; Kushner, S.; Sherr, J.; Vijapurkar, U.; Lim, P.; Eerdekens, M.: Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study (PAL-SCH-301)
A102
Musil, R.; Spellmann, I.; Zill, P.; Bondy, B.; Douhet, A.; Dehning, S.; Severus, E.; Müller, N.; Möller, H. J.; Riedel, M.: Homer 1 and metabotropic glutamate-receptor 5 polymorphisms are associated with response to treatment in schizophrenic patients
A103
Vermeir, M.; Boom, S.; Naessens, I.; Talluri, K.; Eerdekens, M.; Hargarter, L.: Absorption; metabolism and excretion of a single oral dose of 14c-paliperidone 1mg in healthy subjects (PAL-053)
A104
Nazirizadeh, Y.; Hiemke, C.; Vogel, F.; Dragicevic, A.: Therapeutic drug monitoring and objective symptom rating for optimization of antipsychotic drug therapy
A105
Nazirizadeh, Y.; Hiemke, C.; Vogel, F.; Dragicevic, A.: Therapeutic drug monitoring and objective symptom rating for optimization of antipsychotic drug therapy
A106
Karlsson, P.; Hargarter, L.; Dencker, E.; Nyberg, S.; Mannaert, E.; Boom, S.; Talluri, K.; Rossenu, S.; Eriksson, B.; Eerdekens, M.; Farde, L.: Pharmacokinetics and dopamine d2 and serotonin 5-ht2a receptor occupancy of paliperidone in healthy subjects: two open-label, single-dose studies (PAL-115)
A107
Pogarell, O.; Koch, W.; Tatsch, K.; Dehning, S.; Opgen-Rhein, M.; Riedel, M.; Müller, N.; Mulert, C.; Möller, H. J.: Dopaminergic neurotransmission in patients with schizophrenia, individuals at risk, and healthy controls
A108
Rettenbacher, M. A.; Biedermann, F.; Edlinger, M.; Hofer, A.; Kemmler, G. P.; Fleischhacker, W. W.: Neutropenia induced by second generation antipsychotics: a prospective investigation
A109
Richter, D.; Angerhofer, S.; Proksch, C.; Thiele, P.; Friess, E.: Obesity due to psychotropic drugs – a multidisciplinary treatment approach
A110
Schüle, C.; Schmidt, A. K.; Baghai, T. C.; Eser, D.; Wenninger, S.; Rupprecht, R.: Aripiprazole has both agonistic and antagonistic effects on the dopaminergic system in endocrinological challenge tests
A111
Scherk, H.; Menzel, P.; Schneider-Axmann, T.; Wobrock, T.; Usher, J.; Reith, W.; Falkai, P.; Gruber, O.: 5-HTTLPR polymorphism influences amygdala volume
A112
Schmitt, G. J. E.; Dresel, S.; Frodl, T.; La Fougère, C.; Hahn, K.; Möller, H. J.; Meisenzahl, E. M.: Dual-isotope SPECT imaging of striatal dopamine: A comparative study between never treated and haloperidol treated first episode schizophrenic patients
A113
Spellmann, I.; Müller, N.; Musil, R.; Zill, P.; Douhet, A.; Dehning, S.; Cerovecki, A.; Bondy, B.; Möller, H. J.; Riedel, M.: Influences of SNAP-25 polymorphisms on cognitive dysfunctions in schizophrenic patients during an atypical antipsychotic treatment
A114
Tebartz van Elst, L.; Valerius, G.; Büchert, M.; Thiel, T.; Rüsch, N.; Bubl, E.; Hennig, J.; Ebert, D.; Olbrich, H. M.: Increased prefrontal and hippocampal glutamate concentration in first episode paranoid-hallucinatory schizophrenia: evidence from a magnetic resonance spectroscopy study
A115
Zetzsche, T.; Preuss, U. W.; Frodl, T.; Watz, D.; Schmitt, G.; Koutsouleris, N.; Born, C.; Reiser, M.; Möller, H. J.; Meisenzahl, E. M.: In-vivo topography of structural alterations of the anterior cingulate gyrus in schizophrenia
A116
Zilles, D.; Gruber, O.; Burke, S.; Falkai, P.: The influence of genetic loading on working memory performance in schizophrenia
A117
Zill, P.; Büttner, A.; Eisenmenger, W.; Möller, H. J.; Bondy, B.: Differential mRNA expression of the tryptophan hydroxylases 1 and 2 in the human brain: A post mortem study